Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.75
CUR's Cash to Debt is ranked higher than
71% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. CUR: 4.75 )
CUR' s 10-Year Cash to Debt Range
Min: 1.47   Max: No Debt
Current: 4.75

Equity to Asset 0.74
CUR's Equity to Asset is ranked higher than
80% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CUR: 0.74 )
CUR' s 10-Year Equity to Asset Range
Min: -0.81   Max: 0.93
Current: 0.74

-0.81
0.93
F-Score: 4
Z-Score: 9.69
M-Score: -3.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -100566.67
CUR's Operating margin (%) is ranked lower than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. CUR: -100566.67 )
CUR' s 10-Year Operating margin (%) Range
Min: -11385.45   Max: -507.12
Current: -100566.67

-11385.45
-507.12
Net-margin (%) -151066.67
CUR's Net-margin (%) is ranked lower than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. CUR: -151066.67 )
CUR' s 10-Year Net-margin (%) Range
Min: -18029.09   Max: -534.63
Current: -151066.67

-18029.09
-534.63
ROE (%) -157.31
CUR's ROE (%) is ranked higher than
54% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. CUR: -157.31 )
CUR' s 10-Year ROE (%) Range
Min: -1295.32   Max: -147.69
Current: -157.31

-1295.32
-147.69
ROA (%) -93.69
CUR's ROA (%) is ranked higher than
54% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. CUR: -93.69 )
CUR' s 10-Year ROA (%) Range
Min: -481.63   Max: -126.53
Current: -93.69

-481.63
-126.53
ROC (Joel Greenblatt) (%) -5824.32
CUR's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. CUR: -5824.32 )
CUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10806.9   Max: -3891.19
Current: -5824.32

-10806.9
-3891.19
Revenue Growth (%) -100.00
CUR's Revenue Growth (%) is ranked higher than
53% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CUR: -100.00 )
CUR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 26
Current: -100

0
26
EBITDA Growth (%) -10.60
CUR's EBITDA Growth (%) is ranked higher than
74% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CUR: -10.60 )
CUR' s 10-Year EBITDA Growth (%) Range
Min: -17.2   Max: 35.7
Current: -10.6

-17.2
35.7
EPS Growth (%) -13.70
CUR's EPS Growth (%) is ranked higher than
73% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. CUR: -13.70 )
CUR' s 10-Year EPS Growth (%) Range
Min: -40.6   Max: 32.2
Current: -13.7

-40.6
32.2
» CUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CUR Guru Trades in

CUR Guru Trades in

Q1 2014

CUR Guru Trades in Q1 2014

George Soros 191,600 sh (New)
» More
Q2 2014

CUR Guru Trades in Q2 2014

Paul Tudor Jones 12,120 sh (New)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$3.15 - $4.66 $ 2.87-28%0
George Soros 2014-03-31 New Buy0.01%$2.91 - $4.61 $ 2.87-18%191600
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.60
CUR's P/B is ranked higher than
65% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. CUR: 9.60 )
CUR' s 10-Year P/B Range
Min: 3.91   Max: 150.33
Current: 9.6

3.91
150.33
P/S 15726.20
CUR's P/S is ranked higher than
54% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.97 vs. CUR: 15726.20 )
CUR' s 10-Year P/S Range
Min: 43   Max: 451
Current: 15726.2

43
451
EV-to-EBIT -14.20
CUR's EV-to-EBIT is ranked higher than
63% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CUR: -14.20 )
CUR' s 10-Year EV-to-EBIT Range
Min: -26.9   Max: -1.5
Current: -14.2

-26.9
-1.5
Current Ratio 6.18
CUR's Current Ratio is ranked higher than
83% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CUR: 6.18 )
CUR' s 10-Year Current Ratio Range
Min: 0.52   Max: 16.97
Current: 6.18

0.52
16.97
Quick Ratio 6.18
CUR's Quick Ratio is ranked higher than
84% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. CUR: 6.18 )
CUR' s 10-Year Quick Ratio Range
Min: 0.52   Max: 16.97
Current: 6.18

0.52
16.97

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.16
CUR's Price/Net Cash is ranked higher than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 109.33 vs. CUR: 11.16 )
CUR' s 10-Year Price/Net Cash Range
Min: 7.79   Max: 60
Current: 11.16

7.79
60
Price/Net Current Asset Value 11.16
CUR's Price/Net Current Asset Value is ranked higher than
83% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 50.05 vs. CUR: 11.16 )
CUR' s 10-Year Price/Net Current Asset Value Range
Min: 7.79   Max: 60
Current: 11.16

7.79
60
Price/Tangible Book 10.73
CUR's Price/Tangible Book is ranked higher than
70% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9.08 vs. CUR: 10.73 )
CUR' s 10-Year Price/Tangible Book Range
Min: 7.4   Max: 60
Current: 10.73

7.4
60
Earnings Yield (Greenblatt) -7.20
CUR's Earnings Yield (Greenblatt) is ranked higher than
70% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. CUR: -7.20 )
CUR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -7.2

Forward Rate of Return (Yacktman) -16.04
CUR's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CUR: -16.04 )
CUR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -28.6   Max: 58.6
Current: -16.04

-28.6
58.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:7NS.Germany
Neuralstem, Inc. was incorporated in 1997 in the state of Maryland. In 2001 it re-incorporated in the state of Delaware. It is development stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form the proprietary base of its research and development efforts in the area of neural stem cell research, and related technologies. Its technology base, in combination with its know-how, and collaborative projects with major research institutions, provide a competitive advantage and would facilitate the successful development and commercialization of products for use in treatment of an array of neurodegenerative conditions and in regenerative repair of acute disease. The Company is focused on leveraging its key assets, including its intellectual property, its scientific team, its facilities and its capital, to accelerate the advancement of its stem cell technologies. In addition, it is pursuing strategic collaborations with members of academia. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research and collaborative programs. It outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works, and which are accordingly subject to higher FDA requirements, to Charles River Laboratories, Inc., of Wilmington, Massachusetts. The Company's competitors include major multinational pharmaceutical companies, specialty biotechnology companies and chemical and medical products companies operating in the fields of regenerative medicine, cell therapy, tissue engineering and tissue regeneration. Many of these companies are well-established and possess technical, research and development, financial and sales and marketing resources greater than the Company. The Company is subject to various U.S. federal, state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its business.
» More Articles for CUR

Headlines

Articles On GuruFocus.com
Neuralstem Inc. Reports Operating Results (10-Q) Nov 15 2010 
View on CUR Sep 11 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 16 2010 
Neuralstem Inc. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buys Highlight: Neuralstem Inc., Converted Organics Inc., Princeton National Bancorp Inc. Jan 09 2010 
Weekly CEO Buy Highlights: Helix Energy Solutions Group Inc, Neuralstem Inc, Saul Centers Inc, Casua Jan 09 2010 
Weekly CFO Buy Highlights: Neuralstem Inc., New Generation Biofuels Holdings, Converted Organics, Or Jan 04 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Nov 16 2009 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Oct 29 2014
NEURALSTEM, INC. Files SEC form 8-K, Other Events Oct 23 2014
Neuralstem Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual... Oct 23 2014
NEURALSTEM, INC. Files SEC form 8-K, Other Events Oct 09 2014
First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The UC San... Oct 09 2014
NEURALSTEM, INC. Files SEC form 8-K, Other Events Sep 22 2014
Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data Sep 22 2014
NEURALSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Sep 18 2014
NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 11 2014
Coverage initiated on Neuralstem by H.C. Wainwright Sep 08 2014
Neuralstem President And CEO To Present At The 2014 Rodman & Renshaw Annual Global Investment... Sep 05 2014
This tiny biotech company takes the real ice bucket challenge Sep 02 2014
NEURALSTEM, INC. Financials Aug 15 2014
NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 08 2014
CUR: Neuralstem Pipeline Rolling Forward, Tackling Major Unmet Needs Aug 08 2014
Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update Aug 08 2014
NEURALSTEM, INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014
NEURALSTEM, INC. Files SEC form 8-K, Other Events Aug 05 2014
Final Patient Treated In Neuralstem Phase II ALS Stem Cell Trial Aug 04 2014
NEURALSTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK